Related Experiment Videos
Calcium channel blockers and the kidney
1Section of Clinical Pharamcology and Hypertension, Division of Nephrology, Virginia Commonwealth University, Richmond, Virginia, USA. dsica@hsc.vcu.edu
Clinical Cornerstone
|April 27, 2005
Summary
Non-dihydropyridine calcium channel blockers may help slow chronic kidney disease (CKD) progression. Unlike other blood pressure drugs, these medications might reduce protein in urine and lower sympathetic nerve activity.
Area of Science:
- Nephrology
- Cardiovascular Pharmacology
Background:
- Chronic kidney disease (CKD) affects 11% of the US population, with significant increases projected due to an aging demographic.
- Diabetes and hypertension are primary drivers of end-stage renal disease (ESRD), the advanced stage of CKD.
- Proteinuria and sympathetic overactivity are key factors accelerating CKD progression to ESRD.
Purpose of the Study:
- To evaluate the potential of non-dihydropyridine calcium channel blockers (non-DHP CCBs) in managing CKD.
- To compare the effects of non-DHP CCBs with dihydropyridine CCBs (DHP CCBs) on proteinuria and sympathetic activity.
Main Methods:
- Review of experimental and clinical studies on CCB efficacy in CKD.
- Analysis of the mechanisms of action for DHP CCBs versus non-DHP CCBs.
Main Results:
- DHP CCBs (e.g., amlodipine, nifedipine) effectively lower blood pressure but do not significantly reduce proteinuria or sympathetic activity.
- Non-DHP CCBs (e.g., verapamil, diltiazem) exhibit distinct mechanisms that may attenuate sympathetic activity.
- Preliminary evidence suggests non-DHP CCBs could reduce protein excretion in CKD patients.
Conclusions:
- Non-DHP CCBs represent a potential therapeutic strategy for slowing CKD progression.
- Further clinical investigation is warranted to confirm the renoprotective effects of non-DHP CCBs.